Novabridge Biosciences (NBP) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access NBP Annual Income Statement →
Observing income statement movements over recent quarters helps explain how Novabridge Biosciences adapts pricing, costs, and operating efficiency.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing31.36
Research and Development Expense62.91
Total operating costs including COS94.27
Operating income / -loss-94.27
Net Interest Expense / -Income0.00
Investment Income, Interest-7.61
Other loss / -income1.68
Total costs & expenses88.34
Income & Taxes
Income / -loss before income taxes-88.34
Income after income taxes-88.34
Net income / -loss of other equity0.00
Income / -loss from continuing operations-88.34
Discontinued operations0.00
Non-controlling interests-42.07
Net income / -loss-88.34
Income / -loss to shareholder-46.27
EBIT-88.34
EBITD-88.27
EBITDA-88.27
Earnings Per Share
Basic EPS (excl. extra items)-0.48
Extraordinary items0.00
Basic Net EPS-0.48
Basic shares outstanding (Mill. of Units)95.76
Diluted Net EPS-0.48
Diluted average shares (Mill. of Units)95.76
4 historic quarters locked

Sign in to unlock the full Novabridge Biosciences income statement history.

About NBP Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.